Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α

British Journal of Cancer

Volumn 106, Issue 10, 2012, Pages 1587-1590

  Patil, S ^a   Figlin, R A ^b   Hutson, T E ^c   Michaelson, M D ^d   Negrier, S ^e   Kim, S T ^f   Huang, X ^f   Motzer, R J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e CENTRE LÉON BÉRARD   (France)

^f PFIZER INC   (United States)

Author keywords

Metastatic renal cell carcinoma; Progression free survival; Q TWiST; Quality adjusted survival; Sunitinib; TWiST

Indexed keywords

ALPHA INTERFERON; SUNITINIB;

ANALYSIS; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY ADJUSTED TIME WITHOUT SYMPTOM OF DISEASE PROGRESSION OR TOXICITY OF TREATMENT ANALYSIS; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; HUMANS; INDOLES; INTERFERON-ALPHA; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PYRROLES;

EID: 84860725464     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.149     Document Type: Article

References (16)

1. Cella D, Li JZ, Cappelleri JC, Bushmakin A, Charbonneau C, Kim ST, Chen I, Motzer RJ (2008) Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol 26: 3763-3769
2. Cella D, Michaelson MD, Bushmakin AG, Cappelleri JC, Charbonneau C, Kim ST, Li JZ, Motzer RJ (2010) Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferonalpha in a phase III trial: final results and geographical analysis. Br J Cancer 102: 658-664
3. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM. TARGET Study Group (2007a) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134 (Pubitemid 46089673)
4. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay J-O, Bodrogi I, Jagiello-Gruszfeld A. Moore, for the AVOREN Trial Investigators (2007b) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103-2111 (Pubitemid 350296300)
5. Gelber RD, Goldhirsch A (1986) A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 4: 1772-1779 (Pubitemid 17226666)
6. Gelber RD, Goldhirsch A, Cavalli F (1991) Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group. Ann Intern Med 114: 621-628
7. Gelber RD, Goldhirsch A, Cole BF, Wieand HS, Schroeder G, Krook JE (1996) A quality-adjusted time without symptoms of toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst 88: 1039-1045 (Pubitemid 26260489)
8. Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates AS (1989) Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol 7: 36-44 (Pubitemid 19089079)
9. Marcus R, Aultman R, Jost F (2010) A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma. Br J Cancer 102: 19-22
10. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590
11. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib vs interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124 (Pubitemid 46089672)
12. Revicki DA, Feeny D, Hunt TL, Cole BF (2006) Analyzing oncology clinical trial data using the Q-TwiST method: clinical importance and sources for health state preference data. Qual Life Res 15: 411-423
13. Rosendahl I, Kiebert GM, Curran D, Col BF, Weeks JC, Denis LJ, Hall RR (1999) Quality-adjusted survival (Q-TWiST) analysis of EORTC Trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. Prostate 38: 100-109 (Pubitemid 29052948)
14. Sherrill B, Amonkar MM, Stein S, Walker M, Geyer C, Cameron D (2008) Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. Br J Cancer 99: 711-715
15. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28: 1061-1068
16. Zbrozek AS, Hudes G, Levy D, Strahs A, Berkenblit A, DeMarinis R, Parasuraman S (2010) Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma. Pharmacoeconomics 28: 577-584